April 2018

Posted in: Medical Science News | Medical Research News | Medical Condition News Tags: Adolescents, Anxiety, Brain, Cannabis, Compound, Drug Abuse, Education, Epilepsy, Neuroscience, Placebo, Psychology, Research, Schizophrenia … read more at: https://www.news-medical.net/news/20170906/Cannabidiol-appears-to-protect-against-long-term-negative-psychiatric-effects-of-THC.aspx

by

A pharmaceutical drug utilizing a non-psychoactive cannabis compound was given a boost in support from American health officials this week, bringing the naturally-derived cannabidiol (CBD) medication one-step closer to total approval from the Food and Drug Administration (FDA). According to the New York Times, Epidiolex — a seizure-reducing CBD liquid made by British drug firm […]

by

Pharmaceutical-grade cannabidiol (Epidiolex) as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome received positive words from FDA staff in briefing documents issued in advance of an FDA advisory committee meeting that will be held Thursday. The risk-benefit profile established by three clinical trials in LGS and Dravet syndrome “appears to support […]

by

The analysts wrote, “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) […]

by

Cancer, chronic pain, epilepsy, asthma, insomnia, autism, PTSD, inflammatory bowel disease, Parkinson’s – the list of conditions that can be improved, and possibly cured, by medical cannabis keeps growing longer. The powerful plant used to make marijuana and hashish may prove to be the wonder drug of the century. Israeli researchers have long been at […]

by

Pharmaceutical-grade cannabidiol (Epidiolex) as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome received positive words from FDA staff in briefing documents issued in advance of an FDA advisory committee meeting that will be held Thursday. The risk-benefit profile established by three clinical trials in LGS and Dravet syndrome “appears to support […]

by

Published 16 April 2018 Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs. The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities […]

by

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. … read more at: https://www.thepharmaletter.com/article/fda-report-backs-approval-of-cannabis-derived-drug

by

The most interesting thing about owning Pure CBD Exchange is seeing the variety of our clientele. This was also the case in my time operating dispensaries in Aspen and Denver, but diversity and accessibility are on another level in the CBD market. Our site serves customers across the country and throughout the world. We interact […]

by